RxDoctor Payments Data

Joe Leverett, MD

Internal Medicine · Altus, OKNPI 1487697033

Payments from drug & device makers

$1,487in general payments, 2019–2025

Across 91 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$337
  • Boehringer Ingelheim$170
  • GSK$164
  • AstraZeneca$144
  • Bayer$131
  • Amgen$116
  • plus $426 from 10 others

What the payments were for

  • Food & beverage$1,487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,487 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$8,020
Medicare patients
113
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban241$169,007
MounjaroTirzepatide65$77,617
FarxigaDapagliflozin Propanediol72$65,788
OzempicSemaglutide65$64,776
TrulicityDulaglutide41$40,776
JanuviaSitagliptin Phosphate49$32,735
JardianceEmpagliflozin34$30,333
XareltoRivaroxaban24$22,552
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$22,273
Celecoxib305$17,912
Desvenlafaxine Succinate ErDesvenlafaxine Succinate108$11,004
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$10,840
Breo ElliptaFluticasone/Vilanterol21$9,702
Pantoprazole Sodium335$8,932
Atorvastatin Calcium352$7,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$169,007241 claims
Lilly USA, LLCMounjaro, Trulicity$337$118,393106 claims
AstraZenecaFarxiga$144$65,78872 claims
Novo NordiskOzempic$85$64,77665 claims
MerckJanuvia$24$32,73549 claims
Boehringer IngelheimJardiance$170$30,33334 claims
GSKBreo Ellipta, Shingrix$164$13,75941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Altus

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →